Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 3,872 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FAST Clear all

Conditions: Healthy
Interventions: Cefdinir Capsules 300 mg, OMNICEF® 300 mg; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Heart Failure
Interventions: Acute exercise, Cardiac rehabilitation; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Craniofacial Surgery
Interventions: High Dissolving Transitional Food; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Months to 18 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes, Hypertriglyceridemia
Interventions: Saxagliptin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pulmonary Embolism
Interventions: Outpatient Treatment of Pulmonary Embolism; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Breast Cancer
Interventions: D-0502; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut • Minneapolis, Minnesota

Conditions: PVD, Arterial Ulcers
Interventions: High pressure intermittent pneumatic compression (HPIPC), Excercise; Device · Behavioral
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 90 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obesity, Underweight
Interventions: Fasting-refeeding cycle; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Vitamin D Deficiency
Interventions: cholecalciferol; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 69 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: AZD2624; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Blood Draw; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Duarte, California

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation; Drug · Radiation · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 14 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: Osteoarthritis, Knee
Interventions: Performance Clinical Outcome Test; Other
Lead sponsor: Canary Medical; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Frisco, Colorado • South Bend, Indiana • Jackson, Mississippi + 3 more

Conditions: Streptococcus Infection, Pregnancy
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma, Gliosarcoma
Interventions: Temodar and O6-Benzylguanine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes
Interventions: Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Healthy
Interventions: Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Cognitive Function
Interventions: DCTclock; Device
Lead sponsor: Digital Cognition Technologies; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Maitland, Florida

Conditions: Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Travera Inc; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Oakland, California

Conditions: Renal Impairment
Interventions: Glasdegib single 100 mg dose in normal healthy subjects, Glasdegib single 100 mg dose in moderate renal impairment subjects, Glasdegib single 100 mg dose in severe renal impairment subjects; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Aging, Aging Well, Healthy Aging
Interventions: Nitrate enriched beetroot juice, Nitrate depleted beetroot juice, 12 week of combined exercise training; Dietary Supplement · Other
Lead sponsor: Florida Institute for Human and Machine Cognition; Other
Eligibility: 60 Years and older
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Blood Pressure, Neurovascular Control
Interventions: Time-Restricted Feeding; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetes
Interventions: Microneedle patch, Intravenous (IV) catheter, Lancet; Device
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Search by objective public record fields.

Cefdinir Capsules 300 mg, Fasting

Identifying Markers of Exercise Training in Heart Failure

Effect of Novel High Dissolving Transitional Foods

Effects of DPP-4 Inhibition on Triglycerides

Outpatient Treatment of Low-risk Pulmonary Embolism

Food Effect Study of D-0502 Tablet in Healthy Volunteers

The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus

Effect of HPIPC for the Treatment of Ischemic Ulcers in Subjects With PAD

Experimental Approach to Test Predictions of Body Weight Regulation Models

The Effect of a Meal on Vitamin D Absorption

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

Validation of an RLIP76 Assay in Humans

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

A Study of the Construct Validity of Community Walking Speed Data Collected Remotely With the Canary canturioTM te Tibial Extension

Rapid Diagnostic Test for Detection of Group B Streptococcus in Pregnancy

Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM

Linagliptin Inpatient Trial

A Limited Food Effect Study of Gabapentin 800 mg Tablets

Evaluation of DCTclock™ as a Cognitive Assessment Aid

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Glasdegib Renal Impairment Study

Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults

Meal Timing and Blood Pressure

Glucose Measurement Using Microneedle Patches